Glenmark Pharmaceuticals Share Price in Focus; USA Launches Calcium Gluconate Injection USP

Glenmark Pharmaceuticals has added another injectable product to its US business. Its US arm has launched Calcium Gluconate Injection USP in three different pack sizes, giving hospitals and other healthcare buyers another option for the product. 

The launch was announced on August 21, 2026, by Glenmark Pharmaceuticals Inc., USA.  

Three Versions Hit the US Market 

The injection is offered in 1,000 mg/10 mL and 5,000 mg/50 mL single-dose vials, along with a 10,000 mg/100 mL pharmacy bulk package. All three have a concentration of 100 mg/mL.  

Glenmark said that the product is bioequivalent and therapeutically equivalent to the reference drug from Fresenius Kabi USA, which is listed under NDA 208418.  

The Market Has Nearly $70 Million in Sales 

There is already a sizeable market for these presentations in the US. IQVIA data for the 12 months ended June 2026 put sales of the three specified strengths at around $69.9 million. 

The figure includes the brand as well as available therapeutic equivalents.  

Glenmark Wants More Room in Injectables 

Marc Kikuchi, President & Business Head, North America, said the launch will strengthen Glenmark's US injectables business and add to its hospital portfolio. 

He said the company is working to build its injectables business around institutional requirements and supply resilience, while increasing its presence across the US healthcare system.  

Read More: ICICI Bank Share Price in Focus After Board Approves $5 Billion Borrowing Limit! 

Glenmark Pharmaceuticals Share Price Performance  

As of 21 August 2026, at 1:08 PM, Glenmark Pharmaceuticals Ltd share price is trading at ₹2,309.90 per share, reflecting a decline of 0.99% from the previous trading session. 

Conclusion 

Glenmark Pharmaceuticals has launched Calcium Gluconate Injection USP in three formats in the US. The market for the specified strengths recorded approximately $69.9 million in sales during the 12 months ended June 2026 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.